VivoSeq
Other

Pulpotomy

0

Pipeline Programs

3

Active Trials

0

Companies Involved

Pulpotomy is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

23

clinical trials

Completed14 · 61%
Unknown status6 · 26%
Not yet recruiting3 · 13%

Trial Activity

23 trials

3Mixtatin and MTA Vital Pulpotomy in Primary Molars
Not yet recruiting··Phase 1·NCT06478940·50 enrolled
Theracal Pulpotomy in Primary Molars
Completed··Phase 4·NCT04397094·60 enrolled
Biodentine Versus White MTA Pulpotomy
Completed·UUniversity Ghent·Phase 3·NCT01733420·120 enrolled
Pulpotomy Materials in Primary Molars
Completed··N/A·NCT07120321·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)